Next-generation proteomics technology made available to the biotech and pharmaceutical industry through the acquisition of Methuselah Health by leading R&D services provider, RxCelerate

CAMBRIDGE, England - November 22, 2022 - (Newswire.com)

RxCelerate, a leading international out-sourced drug discovery and development platform, today announced the acquisition of drug discovery company Methuselah Health UK Ltd for an undisclosed sum. Methuselah Health was founded in 2015 to discover drugs for age-related diseases driven by proteomic instability and has developed the world's most powerful proteomics platform to power its discovery efforts.

"Until now, the ProQuant™ proteomics technology has only been available for the internal discovery programs at Methuselah Health," said Jill Reckless, CEO at RxCelerate. "But as soon as we saw just how powerful this technology was, we had to add it to our service offering. Through this acquisition, the proprietary ProQuant™ platform will be exclusively available to our clients, giving them access to the best proteomics technology available anywhere."

The development of ProQuant™ was led by David Mosedale, Chief Technical Officer at Methuselah Health since its foundation in 2015. "Proteomics has been an important tool in drug discovery for decades, but existing methods typically focus on the number of proteins identified at the expense of quantitative accuracy. ProQuant™ is a step-change in quantitative accuracy for bottom-up LC-MS-MS-based proteomics, which enables a whole range of applications that are difficult or impossible with existing technology. For example, ProQuant™ can better quantify post-translational modifications, including proteolytic cleavages, in complex protein mixtures, which opens up a new domain for target identification and validation, biomarker discovery and reaction monitoring."

ProQuant™ moves the goalposts for proteomics through proprietary improvements in both the analytical and bioinformatic domains. "The key development," says Mosedale, "was identifying a way to assess quantitative accuracy across the whole proteome simultaneously, even without knowing the true concentration of any of the components. That allowed us to optimize the methodology beyond anything that has been possible before."

ProQuant™ has numerous applications across the drug discovery and development domains. It turbo-charges chemoproteomics during discovery of covalent binders (including protacs), allows the accumulation of post-translational modifications on biologic drugs to be accurately monitored during manufacture, storage and, most importantly, after administration in vivo, and delivers accurate quantitation of protein labelling. 

"Unfortunately, many drug developers do not realise the extent to which the poor quantitative accuracy of traditional proteomics has limited its usefulness. ProQuant™ really is a game-changer," explains Mosedale.

"Over the last several years, we have acquired or developed a unique toolkit of cutting-edge technologies to improve drug discovery and development," said Nick Tait, Chief Financial Officer at RxCelerate. "Galaxy™, our platform to discover better monoclonal antibody drugs at RxBiologics, and RxNfinity™, our dynamic chemical space to improve small molecule discovery, deliver best-in-class capabilities to our clients.  With the acquisition of Methuselah Health and its ProQuant™ proteomics technology, we have taken another step towards our vision of making the best technologies out there available to everyone."

Notes for Editors

About RxCelerate

RxCelerate is an out-sourced drug discovery and development company, founded in Cambridge, UK, in 2013, with a focus on working smarter. It has grown rapidly to become one of the leading providers of drug development services in the United Kingdom. RxCelerate operates a unique model, providing capabilities to discover and develop drugs for clients, designing as well as executing every aspect of the research and development plan.

RxCelerate offers a wide range of services. The biology team specializes in in vivo pharmacology, offering proprietary models of wide range of human diseases, as well as complex cell-based assays. The chemistry team provides medicinal chemistry, including in silico screening and the RxNfinity™ dynamic chemical space, as well as synthesis that integrates seamlessly with the in vitro testing capability. A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches.

RxCelerate has a team of more than 80 employees and consultants based in 25,000 square feet of premium laboratory and office space in the Dorothy Hodgkin Building at the Babraham Research Campus, approximately five miles south of Cambridge, UK, as well as offices in Boston, MA, and San Francisco, CA.

For more information, please visit us at rxcelerate.com and connect with us on Twitter (@RxCelerate). Contact our UK headquarters: [email protected]  Tel: +44 (0)1223 804240. Contact our US headquarters: [email protected]  Tel: +1 (857) 409-6028

Contact Information:
Jill Reckless
CEO
[email protected]
+44 1223 804240


Press Release Service by Newswire.com

Original Source: RxCelerate Acquires Methuselah Health and Launches ProQuant™ World-Beating Proteomics Service

The partnership will bring virtual cardiac rehabilitation and recovery into the homes of patients in Davis Health System's service area.

NEW YORK & ELKINS, W.V. - November 22, 2022 - (Newswire.com)

Recora today announced it has been selected by Davis Health System for its Virtual Cardiac Recovery Program. This program will deliver cardiac rehabilitation in a way that has never been available to the region before, creating new opportunities for patients to recover and transform their lives from the comfort of their homes. 

"Our team is dedicated to improving the cardiac rehabilitation process for our patients. We know how valuable this program is to improving their health and extending their life, but the biggest challenge continues to be patients showing up and sticking with the program," said Kathy Sturm, VP & Chief Nursing Officer, Davis Health System. "With Recora expanding our cardiac rehab program to a virtual environment, we believe this will increase patient participation and eliminate many of the challenges that have prevented patients from engaging, or even being able to participate, especially in the rural community we serve. Given the assistance and coach provided to each patient enrolled in this virtual program, Recora is set up to help patients overcome technical concerns as well."

Through virtual tools provided to patients and on-demand access to care teams and other resources, the program empowers patients to manage their heart health from home while enabling providers and plans to provide comprehensive cardiac care and strengthen patient relationships. Recora's Cardiac Recovery Program moves beyond 12 weeks of rehabilitation to deliver comprehensive care management that focuses on a patient's overall health and wellness.

Recora currently serves cardiac patients in the U.S. across health systems, health plans and medical groups in urban, suburban and rural communities. 

"Davis Health System has taken a critical step forward serving their community in cardiac rehab, and we are proud to partner with them in these efforts," said Recora CEO Abhishek Chandra. "Currently only about 1 in 4 eligible patients ever start a center-based program. The addition of a virtual program with an outreach strategy has been shown to engage more patients overall, including a 15% increase in center-based patients."

Recora's Cardiac Recovery Program has garnered industry-leading results that include:

• 15% hospital readmission rate for Recora patients, versus the national average of 43% across Medicare patients with heart failure at six months.
• 87% Recora cardiac recovery program completion rate, versus the national average of 26%. 
• 80% of patients with hypertension markedly improved their blood pressure due to diet and exercise
• 94% of Recora patients adhere to their cardiac medication.
• 80% improvement of distance and strength gains among Recora patients.

ABOUT RECORA

Recora's mission is to redefine the future of heart health. Recora's Cardiac Recovery Program for health systems, medical groups and health plans makes it easier to recover from a cardiac event through immersive programs delivered online. With Recora, healthcare providers are able to establish a longitudinal relationship with patients and help them live longer, fuller lives. To learn more, visit recora.com. 

ABOUT DAVIS HEALTH SYSTEM

At Davis Health System we have the technology, expertise and services that make us the regional choice for prevention, detection and treatment of disease. As rare as that level of medical advancement is in a rural community, it's CARE that defines us.

Healthcare is people taking care of people. Here, our employees care for families, loved ones, friends, neighbors, visitors… and every person counts; every person benefits from safe and excellent care.

Davis Medical Center (DMC) has been identified as one of the Top 20 Rural Community Hospitals in the nation. According to NRHA, Davis Medical Center outperformed numerous rural hospitals nationwide in an evaluation done by the Chartis Center for Rural Health using iVantage Health Analytics. Hospitals were analyzed in eight areas: inpatient market share, outpatient market share, quality, outcomes, patient perspective, cost, charge and financial stability. 

Contact Information:
Adam Hritzak
Director of Marketing, Recora
[email protected]
614-946-7916

Tracy Fath
VP, Marketing, Davis Health System
[email protected]
(304) 637-3467


Press Release Service by Newswire.com

Original Source: Recora and Davis Health System Partner to Deliver Virtual Cardiac Recovery Program to Patients

The company has seen rapid growth and will be expanding into additional U.S. markets in 2023

PHOENIX - November 21, 2022 - (Newswire.com)

From its humble beginnings as a start-up, the Nurseio digital staffing platform has grown rapidly into a widely used solution for staffing per diem healthcare roles across the U.S.

The Nurseio platform was developed to provide healthcare professionals - including nurses, technicians, caregivers, and nursing assistants - with a convenient way to find and book shifts in their specialties. It has also served as a key alternative to traditional staffing agencies for healthcare facilities, many of which prefer the flexibility that comes with using a web-based app for filling PRN shifts with qualified workers.

Nurseio's app can be used in a browser or on a smartphone via IOS or Android. In addition to convenience, the platform's growth can be attributed in part to a need for such technology. For example, Nurseio makes it easier for facilities and professionals to post and fill shifts on demand, in turn, lending significant support to an industry that is often plagued by staffing shortages and worker burnout.

With Nurseio, there are no commitments to expensive staffing agencies, and facilities get personalized support 24/7 from the platform's team. Meanwhile, healthcare professionals get complete control over their personal schedules, plus the ability to achieve the work-life balance they prefer while receiving premium pay delivered instantly to their bank account after every shift. RNs, LPNs, CNAs, and other professionals can opt for flexible work that fits their schedule and preferences, getting the support they need to prioritize what they value most.

In the year ahead, Nurseio expects to continue to grow and expand into markets across the United States. Currently, the platform has over 33,000 registered healthcare professionals looking for per diem shifts. Facilities are able to quickly fill these shifts by posting them onto Nurseio, where professionals who meet the qualifications and certifications they are looking for can then accept them. 

As Nursieo continues to grow, both healthcare facilities and professionals can expect to see additional opportunities available on the platform and even greater support for streamlining the staffing process. 

About Nurseio

Nurseio is a web and app-based platform that connects healthcare facilities and nursing professionals for PRN and per diem shift work. Through the app, facilities can post and fill open shifts and instantly connect with qualified workers who are ready to accept them, and healthcare professionals can take more control over their careers and work when, where, and how much they want.

Those who are interested in learning more about Nursieo are invited to visit Nurseio's website, where additional information is available regarding the platform's benefits and how it works.

Contact Information:
Callie Ott
Co-Founder and COO
[email protected]

Seth Courson
Co-Founder and CEO
[email protected]


Press Release Service by Newswire.com

Original Source: Nurseio Quickly Becoming One of the Industry's Most Widely Used Per Diem Staffing Platforms

New chip releases large AI models from the cloud and runs them at low power in devices enabling full conversational dialog and complex AI inference inexpensively and at low power.

WATERLOO, Ontario - November 21, 2022 - (Newswire.com)

Applied Brain Research Inc. (ABR) today announced that it has been named a CES® 2023 Innovation Awards Honoree for the ABR Time Series Processor (TSP) AI chip. This year's Consumer Electronics Show (CES) Innovation Awards program received a record-high number of over 2,100 submissions. The announcement was made ahead of CES 2023, the world's most influential technology event, happening January 5th to 8th, 2023 in Las Vegas, NV.

The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA), is an annual competition honoring outstanding design and engineering in 28 consumer technology product categories. Those with the highest rating receive the "Best of Innovation" distinction. An elite panel of industry expert judges, including members of the media, designers, engineers, and more, reviewed submissions based on innovation, engineering and functionality, aesthetics and design.

ABR's Time Series Processor (TSP) chip is based on their revolutionary new algorithm for AI signal processing, the provably optimal Legendre Memory Unit (LMU) neural network. ABR's chip processes time series including speech, language, audio, biosignals, radio frequency signals, network traffic, and more at extremely low power levels, with low latency, and at low cost. A two-minute TSP introduction video is available online. 

The TSP's real-time, AI processing directly on chip enables device innovations such as: 

• Superior full dialog speech and language capability for a few dollars, 
• Complete user voice privacy by processing without requiring the cloud,
• Real-time, multi-channel, accurate signal pattern recognition and anomaly detection, and
• Longer lasting batteries for smart, AI-powered devices. The TSP uses less than 25 milliwatts of power for most applications.

"The LMU algorithm that powers ABR's TSP is a fundamental advance in time series AI processing," said Dr. Chris Eliasmith, co-CEO of ABR. 

"We are honored to have Applied Brain Research's TSP be selected as a CES 2023 Innovation Awards honoree," stated Peter Suma, co-CEO of ABR.

About Applied Brain Research Inc.

ABR is pushing the leading edge in artificial intelligence by designing AI that is inspired by the efficiency of brain circuits. ABR builds AI chips, software tools, and custom solutions for low-power, brain-inspired AI systems applied to devices like smartphones, drones, robots, cars, cameras, clothing, wearables, and sensors. ABR delivers Intelligence for real world applications.

Contact Information:
Peter Suma
co-CEO
[email protected]
1-416-505-8973

Dr. Chris Eliasmith
co-CEO
[email protected]




Press Release Service by Newswire.com

Original Source: ABR Time Series Processor (TSP) AI Chip Named CES 2023 INNOVATION AWARDS HONOREE

MUNICH - November 21, 2022 - (Newswire.com)

neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice, announced the publication titled "Sleep predicts the response to rTMS and CBT in patients with OCD: an open label effectiveness study" in the International Journal of Clinical and Health Psychology. The study confirms the importance of sleep for the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in combination with cognitive behavioral therapy (CBT) as treatment for obsessive-compulsive disorder (OCD).

In this study, the authors investigated if sleep problems may be associated with the response to rTMS in patients with treatment-resistant OCD. All patients were treated at three neurocare group clinics. Study results show that combining rTMS with CBT may be more effective than rTMS alone as 60% of patients with OCD benefit from the combination therapy. Also, 42% of patients with OCD and a major depressive disorder benefit from this combination therapy. The study further concludes that OCD patients with sleeping problems tend to have less favorable treatment outcomes. Therefore, an integrated therapy approach that includes optimizing the patients' sleep during treatment is important.

"The study once again validates the importance of our integrated approach of providing personalized therapy to achieve the best possible and most sustainable outcome for patients suffering from mental health disorders such as OCD," says Tom Mechtersheimer, Founder & CEO of neurocare. "The findings of the study support our recognition that each patient's treatment needs are different and align with our scientific approach to personalized therapy."

In this study, 61 patients with treatment-resistant OCD received a combined treatment of rTMS and cognitive behavioral therapy at three neurocare Group clinicsin Nijmegen, the Haag, and Eindhoven, the Netherlands. The majority received one rTMS protocol aimed at a specific location in the brain (SMA). Patients who had a comorbid depression were treated with the protocol for OCD (SMA) and a protocol that is used for the treatment of depression. 60% of the patients receiving one rTMS protocol showed a decrease of at least 35% in obsessive compulsive complaints, as measured by the Y-BOCS. 42% of the patients receiving the two rTMS protocols showed a decrease of at least 35% in obsessive compulsive complaints. Patients also reported a large effect on depressive symptoms. Patients with sleeping problems had a less favorable outcome.

The full publication in the International Journal of Clinical and Health Psychology of the article "Sleep predicts the response to rTMS and CBT in patients with OCD: an open label effectiveness study" can be accessed here. 

About neurocare group AG:
neurocare is innovating mental health and performance. We offer the first digital therapy platform (DTP) empowering clinicians to deliver best practice. Our integrated and personalized therapy approach is based on a strong clinical science background with over 20 years of research and technology development. Our business is driven by two strong growth channels: building our own clinics and providing our unique DTP to third parties. We currently treat about 2,800 patients annually in our own clinics and serve many third-party practices with our personalized therapy approach, our technologies and related training/onboarding. www.neurocaregroup.com 

Contact:
Pamela Keck
neurocare group AG
[email protected] 
 

Contact Information:
Pamela Keck
[email protected]
+49 89 356476754


Press Release Service by Newswire.com

Original Source: neurocare group AG Announces Publication Confirming the Importance of Sleep for Effectiveness of Combined rTMS and CBT for OCD